Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour. GBM development is is closely associated with inflammation status and immune response. The neutrophil-to-lymphocyte ratio (NLR) is a marker of host immune response and its elevation has recently been shown to be a poor prognostic factor in many malignancies including colon, prostate, lung, and bladder cancer. We aimed to investigate the prognostic value of preoperative NLR in GBM patients.
Between 2010 and 2016; 104 patients had surgery for GBM and were assessed for consideration of adjuvant therapy at our institution. Of these, 80 patients with an evaluable pre-corticosteroid full blood count result were identified and included in the final analysis.
The mean tumor diameter was 41mm, most of them were found in the right hemisphere (56%) and in the temporal lobe (27.5%). 85% of the patients received adjuvant chemoradiotherapy (with temozolamide). Median overall survival was 13.4 moths. Patients with NLR 4. But this difference was not statistically significant (p > 0.05).
Our results suggest that pretreatment NLR could be a useful marker for predicting prognosis in GBM patients but large scale trials are needed to confirm this.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.